Hi Grainsfsand,
An interesting point is that while Amylyx was running up $US381 Million in sales, 43%of patients were discontinuing it's use due to side effects. So $US500 million would probably be closer in the first year.
Also@Densy posted a nice table recently showing the average MC of a bio company Vs sales. 8.3 I think it was.
Cheers
Pharmaust - Media & News, page-96
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
16.5¢ |
Change
-0.005(2.94%) |
Mkt cap ! $80.22M | |||
| Open | High | Low | Value | Volume |
| 17.0¢ | 18.0¢ | 16.5¢ | $210.6K | 1.236M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 274938 | 16.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.0¢ | 15000 | 2 |
View Market Depth
| Last trade - 16.10pm 15/08/2024 (20 minute delay) ? |
| PAA (ASX) Chart |